Xu Hang, Yao Yuanfei, Meng Fanyu, Qian Xu, Jiang Xiaofeng, Li Xiaoxi, Gao Zhuo, Gao Lu
From the Department of Pharmacy, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China (HX); School of Life Science and Technology, Harbin Institute of Technology, Harbin, China (YY); School of Public Health, Harbin Medical University, Harbin, China (FM); Department of Neuro-Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA (XQ); Department of Clinical Laboratory, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China (XJ, ZG); The Center of Metabolic Disease Research, Nanjing Medical University, Nanjing, China (XL, ZG); Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA (ZG); College of Life Sciences, Northeast Agricultural University, Harbin, China (LG); and Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA (LG).
Medicine (Baltimore). 2015 Nov;94(44):e1558. doi: 10.1097/MD.0000000000001558.
Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer-related deaths worldwide. The high mortality of ESCC is mainly due to late diagnosis. Current detection methods have their own weakness, including high costs and invasive procedures. MicroRNA assays are shown to have great potential to be accurate and noninvasive methods for ESCC screening. In this study, we selected 3 microRNAs, miR-10b, miR-29c, and miR-205, to assess their diagnostic value in ESCC screening. Fifty ESCC patients and 50 healthy controls are recruited in our study. Blood samples are collected from the total 100 participants. MicroRNAs were extracted from serum and quantified by qRT-PCR, which their relative expressions were normalized by internal control, U6 snRNA. Statistical analyses were conducted to compare microRNAs level as well as other clinical characteristics between 2 groups. The levels of serum miR-29c and miR-205 were significantly downregulated in ESCC patients compared with healthy volunteers. In contrast, ESCC patients appeared to have a higher level of miR-10b than healthy controls. ROC curve analyses revealed that the AUC value for miR-10b, miR-29c, and miR-205 were 0.85 (95% CI: 0.79-0.93; sensitivity = 76%; specificity = 84%), 0.72 (95% CI: 0.62-0.82; sensitivity = 68%; specificity = 68%), and 0.72 (95% CI: 0.62-0.83; sensitivity = 70%; specificity = 64%), respectively, suggesting that miR-10b, miR-29c, and miR-205 have great potential to be noninvasive screening tools for ESCC detection.
食管鳞状细胞癌(ESCC)是全球癌症相关死亡的主要原因之一。ESCC的高死亡率主要归因于诊断延迟。目前的检测方法都有其自身的弱点,包括成本高和侵入性操作。微小RNA检测显示出作为ESCC筛查的准确且非侵入性方法的巨大潜力。在本研究中,我们选择了3种微小RNA,即miR-10b、miR-29c和miR-205,以评估它们在ESCC筛查中的诊断价值。我们的研究招募了50例ESCC患者和50名健康对照。从总共100名参与者中采集血样。从血清中提取微小RNA并通过qRT-PCR进行定量,其相对表达通过内参U6 snRNA进行标准化。进行统计分析以比较两组之间的微小RNA水平以及其他临床特征。与健康志愿者相比,ESCC患者血清miR-29c和miR-205水平显著下调。相反,ESCC患者的miR-10b水平似乎高于健康对照。ROC曲线分析显示,miR-10b、miR-29c和miR-205的AUC值分别为0.85(95%CI:0.79-0.93;敏感性=76%;特异性=84%)、0.72(95%CI:0.62-0.82;敏感性=68%;特异性=68%)和0.72(95%CI:0.62-0.83;敏感性=70%;特异性=64%),这表明miR-10b、miR-29c和miR-205作为ESCC检测的非侵入性筛查工具具有巨大潜力。